Form 8-K

8-K — HCW Biologics Inc.

Accession: 0001493152-26-030236

Filed: 2026-06-26

Period: 2026-06-24

CIK: 0001828673

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Material Modifications to Rights of Security Holders

Item: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-3.1 (ex3-1.htm)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

--12-31

0001828673

2026-06-24

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): June 24,

2026

HCW

Biologics Inc.

(Exact

name of Registrant as Specified in Its Charter)

Delaware

001-40591

82-5024477

(State

or Other Jurisdiction

Incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

2929

N. Commerce Parkway

Miramar,

Florida

33025

(Address

of Principal Executive Offices)

(Zip

Code)

Registrant’s

Telephone Number, Including Area Code: 954

842-2024

(Former

Name or Former Address, if. Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.0001 per share

HCWB

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities 3Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item

3.03 Material Modification to Rights of Security Holders.

June 15, 2026, at the Annual Meeting of Stockholders of HCW Biologics Inc., a Delaware corporation (the “Company”), the stockholders

granted to the Board of Directors of the Company the authority to effectuate a reverse split of the Company’s issued and outstanding

shares of common stock, par value $0.0001 per share (the “Common Stock”). On June 24, 2026, the Board of Directors (the “Board”)

approved a reverse stock split at a ratio of 1 - for - 6 (one for six) shares (the “Reverse Stock Split”). The Company expects

that the effective time of the Reverse Stock Split will be at or about 12:01 a.m. Eastern time on Tuesday, June 30, 2026 (the “Effective

Date”), with the Common Stock trading on The Nasdaq Capital Market (“Nasdaq”) on a reverse split-adjusted basis under

the Company’s existing trading symbol, “HCWB,” at the market open on Tuesday, June 30, 2026.

Reasons

for Reverse Stock Split

of June 24, 2026, the Company’s shares traded over $1.00 per share for 27 consecutive trading days; however, the trading price

was sustained at the minimum level. According to the terms contained in a decision letter from the Nasdaq Hearings Panel (the “Panel”)

delivered on May 29, 2026, any future noncompliance of the Common Stock with Nasdaq Listing Rule 5550(a), or (the “Bid

Price Rule”) prior to September 22, 2026, will result in automatic delisting of the Common Stock. The Company is effecting

the Reverse Stock Split now in an effort to ensure the Company remains compliant with the Bid Price Rule as well as the terms required

by the Panel.

Effects

of the Reverse Stock Split

Effective

Date; Symbol; CUSIP Number. The Reverse Stock Split will become effective with Nasdaq, and the Common Stock will begin

trading on a reverse split-adjusted basis, at the open of business on the Effective Date. In connection with the Reverse

Stock Split, the CUSIP number for the Common Stock will change to 40423R303.

Split

Adjustment; Treatment of Fractional Shares. On the Effective Date, the total number of shares of Common Stock held by each stockholder

of the Company will be converted automatically into the number of shares of Common Stock equal to: (i) the number of issued and outstanding

shares of Common Stock held by each such stockholder immediately prior to the Reverse Stock Split divided by (ii) six (6). Any fractional

share of Common Stock that would otherwise result from the Reverse Stock Split will be rounded up to the next whole share and, as such,

any stockholder who otherwise would have held a fractional share after giving effect to the Reverse Stock Split will instead hold one

whole share of the post-Reverse Stock Split Common Stock after giving effect to the Reverse Stock Split. As a result, no fractional shares

will be issued in connection with the Reverse Stock Split and no cash, scrip, or other consideration will be paid in connection with

any fractional shares that would otherwise have resulted from the Reverse Stock Split. The Company intends to treat stockholders holding

shares of Common Stock in “street name” (that is, held through a bank, broker, or other nominee) in the same manner as stockholders

of record whose shares of Common Stock are registered in their names. Banks, brokers, or other nominees will be instructed to effect

the Reverse Stock Split for their beneficial holders holding shares of the Company’s Common Stock in “street name”;

however, these banks, brokers, or other nominees may apply their own specific procedures for processing the Reverse Stock Split.

Also,

on the Effective Date, all options and warrants of the Company outstanding immediately prior to the Reverse Stock Split will be adjusted

by (i) dividing the number of shares of Common Stock into which the options and warrants are exercisable or convertible by six (6) and

(ii) multiplying the exercise or conversion price thereof by six (6), all in accordance with the terms of the plans, agreements, or arrangements

governing such options and warrants and subject to rounding up to the nearest whole share.

Non-Certificated

Shares. Those Company stockholders who hold their

shares in electronic form do not need to take any action, as the effect of the Reverse Stock Split will automatically be reflected in

their accounts with the Company’s transfer agent. Those stockholders who hold their shares in “street name” will receive

instructions from their bank, broker, or nominee.

Amended

Certificate of Incorporation. The Company effected the Reverse Stock Split pursuant to the Company’s filing of a Certificate

of Amendment of Certification of Incorporation with the Secretary of State of the State of Delaware on June 24, 2026 to advance the first

day of trading on a reverse split-adjusted basis to the Effective Date, all in accordance with the Delaware General Corporation

Law. The Certificate of Amendment of Certificate of Incorporation is expected to become effective at or about 12:01 a.m. Eastern time

on the Effective Date. A copy of the Certificate of Amendment of Certificate of Incorporation is attached as Exhibit 3.1 to this Current

Report.

Stockholder

Approval. As disclosed above and as reported on Form 8-K filed on June 15, 2026, the Company’s stockholders approved an amendment

to the Company’s Certificate of Incorporation to implement one or more reverse stock splits of the outstanding shares of the Common

Stock (as necessary to maintain a listing of the Common Stock on Nasdaq in an aggregate range from one-for-five (1:5) up to one-for-twenty

(1:20), or anywhere between, all as determined in the sole discretion of the Company’s Board of Directors. The stockholder approval

occurred at the Annual Meeting of Stockholders held on June 15, 2026 at 10 a.m. Eastern time.

Capitalization.

Prior to the Reverse Stock Split, the Company was authorized to issue 250,000,000 shares of Common Stock. There will be no change in

the number of authorized shares as a result of the Reverse Stock Split. As of June 25, 2026, there were 9,581,079 shares of Common Stock

outstanding. As a result of the Reverse Stock Split, there will be approximately 1,596,849 shares of Common Stock outstanding (subject

to adjustment due to the effect of rounding fractional shares into whole shares). The number of shares of preferred stock that the Company

is authorized to issue will not be impacted; none is currently issued and outstanding.

Immediately

after the Reverse Stock Split, each stockholder’s relative ownership interest in the Company and proportional voting power will

remain virtually unchanged except for minor changes and adjustments that will result from rounding fractional shares of Common Stock

into whole shares.

Forward

Looking Statements

This

Current Report on Form 8-K contains forward-looking statements. Forward-looking statements may include, but are not limited to, statements

related to the Reverse Stock Split, the effectiveness of the Certificate of Amendment of Certificate of Incorporation, and the Company’s ability to maintain compliance with Nasdaq’s minimum bid price requirement, as well as statements,

other than historical facts, that address activities, events, or developments that the company intends, expects, projects, believes,

or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,”

“hopes,” “may,” “anticipates,” “should,” “intends,” “plans,”

“will,” “expects,” “estimates,” “projects,” “positioned,” “strategy,”

and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of

historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements

in this Current Report on Form 8-K are made as of the date of this Current Report on Form 8-K, and the Company undertakes no duty to

update or revise any such statements, whether as a result of new information, future events, or otherwise. Forward-looking statements

are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the Company’s

control. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking

statements are described in the sections titled “Risk Factors” in the Company’s filings with the Securities and Exchange

Commission, including its most recent Annual Report on Form 10-K filed on March 31, 2026, as well as Quarterly Reports on Form 10-Q,

and Current Reports on Form 8-K, and include whether the Company will be successful in maintaining the listing of its Common Stock on

Nasdaq and the effects of the Reverse Stock Split.

Item

5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

The

information set forth in Item 3.03 is hereby incorporated by reference into this Item 5.03.

Item

7.01 Regulation FD Disclosure.

June 26, 2026, Company issued a press release announcing the Reverse Stock Split. A copy of the press release is furnished as Exhibit

99.1 to this Current Report on Form 8-K.

Exhibit

99.1 is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall

it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

3.1

Certificate of Amendment of Certificate of Incorporation, filed June 24, 2026.

99.1

Press release, dated June 26, 2026, announcing reverse stock split.

104

Cover Page Interactive Data File (embedded within the

Inline XBRL document).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

HCW BIOLOGICS INC.

Date:

June 26, 2026

By:

/s/

Hing Wong

Hing C. Wong, Founder and Chief Executive Officer

EX-3.1

Filename: ex3-1.htm · Sequence: 2

Exhibit

3.1

FORM

STATE

OF DELAWARE

CERTIFICATE

OF AMENDMENT

CERTIFICATE OF INCORPORATION

The

corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certifies:

FIRST:

That by a unanimous consent in lieu of a special meeting of the Board of Directors of

HCW

Biologics Inc.

resolutions

were duly adopted setting forth a proposed second amendment of the Restated Certificate of Incorporation of said corporation, declaring

said amendment to be advisable and calling a meeting of the stockholders of said corporation for consideration thereof. The resolution

setting forth the proposed amendment is as follows:

RESOLVED,

that Article IV, Section 1 of the Restated Certificate of Incorporation of this corporation be amended by adding the following new paragraph

at the end of Article IV, Section 1:

Upon

the effectiveness (the “Effective Time”) of this Certificate of Amendment to the Restated Certificate of Incorporation

with the Secretary of State of the State of Delaware, each six (6) shares of this corporation’s Common Stock, par value $0.0001

per share, issued and outstanding immediately prior to the Effective Time (the “Old Common Stock”) shall automatically

without further action on the part of this corporation or any holder of Old Common Stock, be reclassified, combined, converted, and changed

into one (1) fully paid and nonassessable share of common stock, par value $0.0001 per share

(the “New Common Stock”), subject to the treatment of fractional share interests as described below (the “Reverse

Stock Split”). The conversion of the Old Common Stock into New Common Stock will be deemed to occur at the Effective Time.

From and after the Effective Time, certificates representing the Old Common Stock shall represent the number of shares of New Common

Stock into which such Old Common Stock shall have been converted pursuant to this Amendment. Holders who otherwise would be entitled

to receive fractional share interests of New Common Stock upon the effectiveness of this reverse stock split shall be entitled to receive

one whole share of New Common Stock in lieu of any fractional share created as a result of such Reverse Stock Split.

SECOND:

That, pursuant to resolution of its Board of Directors, a special meeting of the stockholders of said corporation was duly called and

held upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at which meeting the necessary

number of shares as required by statute were voted in favor of the amendment.

THIRD:

That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of

Delaware.

FOURTH:

That said amendment shall be effective as of 12:01 a.m. Eastern time on June 30, 2026.

WITNESS WHEREOF, said corporation has caused this certificate to be signed this 24th day of June, 2026.

By:

/s/

Hing Wong

Authorized

Officer

Title:

Founder

and Chief Executive Officer

Name:

Hing

C. Wong

EX-99.1

Filename: ex99-1.htm · Sequence: 3

Exhibit

99.1

HCW

Biologics Announces 1-for-6 Reverse Stock Split

Effective

on June 30, 2026

Company

completed 28 consecutive trading days above $1.00 per share on June 25, 2026

Reverse

stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings Panel

Miramar,

FL – June 26, 2026 – HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a

U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases

promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated

dysplasia, today announced that its Board of Directors has approved a 1-for-6 reverse stock split of the Company’s common stock,

par value $0.0001 (“Common Stock”), which will be effective at 12:01 a.m. Eastern Time on June 30, 2026. The Company’s

Common Stock will be traded on The Nasdaq Capital Market on a reverse split-adjusted basis beginning on June 30, 2026, under the Company’s

existing trading symbol “HCWB.”

After

an appeal, the Company received a decision letter from a Nasdaq Hearings Panel (the “Panel”) on May 29, 2026, which provided

a path to compliance with Nasdaq Listing Rule 5550(a) (the “Bid Price Rule”). The primary requirement in

the Panel’s decision letter was that the Company’s Common Stock must trade above $1.00 per share for a period

of 20 days prior to July 29, 2026. The Company’s Common Stock completed 20 trading days above $1.00 per share as of

June 12, 2026, and has continued to trade around $1 per share since that time. Given the Panel’s stated requirements, including

that the Company maintain compliance with the Bid Price Rule or face immediate delisting, the reverse stock split is intended to

ensure compliance with the Bid Price Rule as well as other conditions required by the Panel. The new CUSIP number following the reverse

stock split will be 40423R303. The Company filed the relevant amendments to its Certificate of Incorporation with the Delaware Secretary

of State on June 24, 2026 to effect the reverse split on June 30, 2026.

The

reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in

the Company, except to the extent that the reverse stock split would otherwise result in any of the Company’s stockholders owning

a fractional share as described in more detail below.

The

reverse stock split will reduce the number of shares of Common Stock issued and outstanding from 9,581,079 (the number of issued and

outstanding shares as of June 25, 2026) to approximately 1,596,849. The total authorized number of shares of Common Stock will remain

at 250,000,000 shares of Common Stock and the per-share par value will remain at $0.0001 per share. No fractional shares will

be issued in connection with the reverse stock split. Each stockholder who would otherwise be entitled to receive a fraction of a share

of the Company’s Common Stock will instead receive one whole share of Common Stock in connection with the reverse stock split.

of the effective date of the reverse stock split, the number of shares of Common Stock available for issuance under the Company’s

equity incentive plans and issuable upon the exercise of stock options and warrants outstanding immediately prior to the reverse stock

split will be proportionately affected by the reverse stock split. The exercise prices of the Company’s outstanding options and

warrants will be adjusted in accordance with their respective terms.

Equiniti

Trust Company LLC (“Equiniti”), the Company’s transfer agent, will act as the exchange agent for the reverse stock

split. Those Company stockholders who hold their shares in electronic form do not need to take any action, as the effect of the Reverse

Stock Split will automatically be reflected in their accounts with Equiniti. Those stockholders who hold their shares in “street

name” will receive instructions from their bank, broker, or nominee.

About

HCW Biologics:

HCW

Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion

immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated

dysplasia. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally

change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and

in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development

and financing strategy is to focus on its business development programs. See the Company Pipeline at https://hcwbiologics.com/pipeline/

Forward-Looking

Statements:

This

press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933, as amended, and

Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking

statements. Such forward-looking statements include, among other things, statements relating to the timing, consummation, and impact

of the reverse stock split, the Company’s ability to maintain compliance with Nasdaq’s minimum bid price requirement,

and the actions of third parties, including Equiniti, with respect to the reverse stock split. Actual results could differ from those

projected in any forward-looking statement due to numerous factors. Such factors include, among others, our ability to maintain compliance

with Nasdaq’s continued listing rules. These forward-looking statements are made as of the date of this press release, and we assume

no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected

in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should

also refer to the risk factor disclosure set forth in the reports and other documents we file with the Securities and Exchange Commission,

or the SEC, available at www.sec.gov, including, without limitation, the Company’s most recent Annual Report on Form 10-K filed

on March 31, 2026, and other SEC filings.

Company

Contact:

Rebecca

Byam

CFO

HCW

Biologics Inc.

rebeccabyam@hcwbiologics.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 4

Binary file (3829 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 20

v3.26.1

Cover

Jun. 24, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 24, 2026

Current Fiscal Year End Date

--12-31

Entity File Number

001-40591

Entity Registrant Name

HCW

Biologics Inc.

Entity Central Index Key

0001828673

Entity Tax Identification Number

82-5024477

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2929

N. Commerce Parkway

Entity Address, City or Town

Miramar

Entity Address, State or Province

Entity Address, Postal Zip Code

33025

City Area Code

954

Local Phone Number

842-2024

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

HCWB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

true

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name:

dei_CurrentFiscalYearEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:gMonthDayItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration